Clarametyx Biosciences Promotes Key Executives to Accelerate Clinical Pipeline

Veronica Hall, PhD, named Chief Development Officer and Brendan Doran, PharmD, promoted to Chief Operating Officer

Apr. 2, 2026 at 4:38pm

Got story updates? Submit your updates here. ›

Clarametyx Biosciences, a clinical-stage biotech company developing immune-enabling therapies and vaccines, has promoted two key executives to strengthen its leadership team and accelerate the advancement of its clinical development efforts.

Why it matters

The promotions of Veronica Hall and Brendan Doran underscore Clarametyx's commitment to rapidly progress its pipeline of innovative treatments, which could have a significant impact on patient care if successfully developed and brought to market.

The details

Veronica Hall, PhD, has been promoted to the role of Chief Development Officer and Head of R&D, while Brendan Doran, PharmD, has been elevated to Chief Operating Officer. These strategic appointments are designed to bolster Clarametyx's clinical development capabilities as it works to deliver its therapeutic innovations to patients.

Clarametyx Biosciences announced the executive promotions on April 2, 2026.

The players

Veronica Hall, PhD

Newly promoted Chief Development Officer and Head of R&D at Clarametyx Biosciences, where she will oversee the advancement of the company's clinical pipeline.

Brendan Doran, PharmD

Newly promoted Chief Operating Officer at Clarametyx Biosciences, responsible for overseeing the company's day-to-day operations and supporting its clinical development efforts.